SCHEMBL15042485

SCHEMBL15042485

O=[PH](O)OCCCNCc1ccc(OCCCCCc2cccc(C(F)(F)F)c2)c(-c2ccco2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 2/20 0.43
KDM4E B2RXH2 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ROCK1 Q13464 1/20 0.39
HTR6 P50406 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
PIP4K2A P48426 1/20 0.36
PIK3CG P48736 1/20 0.36
FFAR4 Q5NUL3 1/20 0.35
DPP7 Q9UHL4 1/20 0.34
POLB P06746 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGAV P06756 1/20 0.34
ITGA2B P08514 1/20 0.34
S1PR1 P21453 2/20 0.33
S1PR3 Q99500 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15746722 0.94 SCN8A (0.46) SCN8AKDM4ETDP1ROCK1HTR6
SCHEMBL15042586 0.89 KDM4E (0.39) KDM4EHTR6HDAC1POLBS1PR1
SCHEMBL15042607 0.89 ALDH1A1 (0.39) KDM4EMEN1KMT2APOLBS1PR1
SCHEMBL15042524 0.88 CHRM2 (0.40) KDM4EHTR6MEN1KMT2AHDAC1
SCHEMBL15042476 0.87 S1PR2 (0.37) SCN8AKDM4EMEN1KMT2AS1PR1
SCHEMBL15022395 0.87 S1PR2 (0.48) SCN8AKDM4ETDP1ROCK1HTR6
SCHEMBL15042634 0.87 CHRM2 (0.43) SCN8AKDM4EHTR6MEN1KMT2A
SCHEMBL15042553 0.86 ALDH1A1 (0.36) SCN8AKDM4EMEN1KMT2AS1PR1
SCHEMBL15042486 0.85 KMT2A (0.39) KDM4EMEN1KMT2APOLBS1PR1
SCHEMBL15042484 0.85 S1PR2 (0.42) KDM4EMEN1KMT2AS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828973-B2 Compounds as receptor modulators with therapeutic utility ALLERGAN, INC. (US) 2014-09-09 US disclosed
US-20140221317-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY ALLERGAN, INC. (US) 2014-08-07 US disclosed
US-8741875-B2 Compounds as receptor modulators with therapeutic utility ALLERGAN, INC. (US) 2014-06-03 US disclosed
US-20130157982-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY ALLERGAN, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221317-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY S1PR1, S1PR3, S1PR2 SCN8A 1316/4885KDM4E 3276/4885TDP1 3089/4885
US-20130157982-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY S1PR1, S1PR3, S1PR2 SCN8A 1316/4885KDM4E 3276/4885TDP1 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.